Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: A European cross-over controlled trial in a rare disease

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 9, 2014, Pages 1494-1502

  Gaillard, Ségolène ^a,b,c   Dupuis Girod, S ^b,d,e,f   Boutitie, F ^b,c,g,h   Riviere S ⁱ   Moriniere S ^j   Hatron, P Y ^k   Manfredi, G ^l   Kaminsky, P ^m   Capitaine, A L ⁿ   Roy, P ^b,c,h,i   Gueyffier, F ^a,b,c   Plauchu, H ^d,e,f,g  

^a Inserm   (France)

^b UNIVERSITÉ LYON 1   (France)

^c LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^d LOUIS PRADEL HOSPITAL   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f CROIX ROUSSE HOSPITAL   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h UNIVERSITÉ DE LYON   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j CHU BRETONNEAU   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l MAGGIORE HOSPITAL   (Italy)

^m CHU NANCY BRABOIS   (France)

ⁿ University of Poitiers   (France)

more..

Author keywords

Epistaxis; Hereditary hemorrhagic telangiectasia; Osler rendu disease; Randomized controlled trial; Tranexamic acid

Indexed keywords

HEMOGLOBIN; PLACEBO; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ADULT; AGED; ALLERGY; ARTERIOVENOUS MALFORMATION; ARTICLE; BRAIN ARTERIOVENOUS MALFORMATION; CONTROLLED STUDY; CONVULSION; CROSSOVER PROCEDURE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FAINTNESS; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PULMONARY ARTERIOVENOUS FISTULA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RENDU OSLER WEBER DISEASE; STOMACH DISEASE; THROMBOPHLEBITIS; VEIN THROMBOSIS; VERTIGO; VOMITING; DOUBLE BLIND PROCEDURE; EUROPE; HEMORRHAGE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); RARE DISEASE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EPISTAXIS; EUROPE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; QUALITY OF LIFE; RARE DISEASES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TRANEXAMIC ACID; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908503787     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12654     Document Type: Article

References (22)

1. Bideau A, Plauchu H, Brunet G, Robert J. Epidemiological investigation of Rendu-Osler disease in France: its geographical distribution and prevalence. Popul 1989; 44: 3-22.
2. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91:66-7.
3. Plauchu H, de Chadarevian JP, Bideau A, Robert JM. Agerelated clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-7.
4. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345-51.
5. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13: 189-95.
6. Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, Mitchell G, Drouin E, Westermann CJ, Marchuk DA. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363: 852-9.
7. Haitjema T, Balder W, Disch FJ, Westermann CJ. Epistaxis in hereditary haemorrhagic telangiectasia. Rhinology 1996; 34:176-8.
8. Karapantzos I, Tsimpiris N, Goulis DG, van Hoecke H, van Cauwenberge P, Danielides V. Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire. Eur Arch Otorhinolaryngol 2005; 262: 830-3.
9. Folz BJ, Tennie J, Lippert BM, Werner JA. Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease. Rhinology 2005; 43: 40-6.
10. Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med 2001; 161: 767.
11. Sabba C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 926.
12. Lozano M. Tranexamic acid in hereditary hemorrhagic telangiectasia. N Engl J Med 2002; 346: 457.
13. Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, Ramirez JR, Morales-Angulo C, Zarrabeitia R, Perez-Molino A, Bernabéu C, Botella LM. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. J Thromb Haemost 2007; 97: 254-62.
14. Shovlin CL, Sulaiman NL, Govani FS, Jackson JE, Begbie ME. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. J Thromb Haemost 2007; 98: 1031-9.
15. Bick RL. Hereditary hemorrhagic telangiectasia and disseminated intravascular coagulation: a new clinical syndrome. Ann N Y Acad Sci 1981; 370: 851-4.
16. Gluud LL, Klingenberg SL, Langholz SE. Systematic review: tranexamic acid for upper gastrointestinal bleeding. Aliment Pharmacol Ther 2008; 27: 752-8.
17. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebocontrolled trial. Lancet 2010; 376: 23-32.
18. Rivière S, Pelenc D, Dupuis GirodS, Lorcerie B, Kaminsk P, Lequellec A, Plauchu H, on behalf of the European Network of HHT Disease. Hereditary Hemorrhagic Telanglectasia and Venous Thromboembolis. Proceedings of the 8th International Hereditary Hemorrhagic Telanglectasia Scientific Conference in Santander, Spain. Hematology Meeting Reports 2009; 3: 54.
19. Kakar PN, Gupta N, Govil P, Shah V. Efficacy and Safety of Tranexamic Acid in Control of Bleeding Following TKR: a Randomized Clinical Trial. Indian J Anaesth 2009; 53: 667-71.
20. Alvarez JC, Santiveri FX, Ramos I, Vela E, Puig L, Escolano F. Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. Transfusion 2008; 48: 519-25.
21. Shakur H, Elbourne D, Gulmezoglu M, Alfirevic Z, Ronsmans C, Allen E, Roberts I. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 2010; 11: 40.
22. Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette D, Valette PJ, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012; 307: 948-55.